IMNN is trading 5.5% down at $2.17 today despite a lack of fresh company-specific news, regulatory filings, or clinical trial readouts to explain the move.
- The decline appears to be driven by standard volatility typical of thinly traded biotech names, especially as major market indices are currently trading modestly higher.
- Recent analyst coverage remains positive, with the company maintaining a Strong Buy rating and optimistic price targets.